NUVB

SEC source: 0001415889-24-010722 · form4-04112024_100415.xml · derivative · entry 1

Sjogren Colleen · CIK 0002017751 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 500,000 shares

Expires 2034-04-08

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 3/27/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0001415889-24-010738 · form4-04122024_010452.xml · nonDerivative · entry 3

Cui Xiangmin · CIK 0001487815 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Decheng Anbio Limited

Disclosed balance after: 4,183,002

F1 · shares: Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among Nuvation Bio Inc. (the "Issuer"), AnHeart Therapeutics Ltd. ("AnHeart"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer ("Merger Sub I"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer ("Merger Sub II"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the "First Merger"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer (the "Second Merger" and, collectively with the First Merger, as appropriate, the "Merger").

F6 · price: Received in exchange for 7,200,000 Series A Preferred shares, 685,714 Series A+ Preferred shares and 487,231 Series B Preferred shares of AnHeart in connection with the Merger (as described in footnote 1) on April 9, 2024.

F7 · ownership.nature: These securities are owned directly by Decheng Anbio Limited ("SPV"). The Reporting Person is a director of SPV. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-010738 · form4-04122024_010452.xml · nonDerivative · entry 2

Cui Xiangmin · CIK 0001487815 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP

Disclosed balance after: 1,675,236

F1 · shares: Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among Nuvation Bio Inc. (the "Issuer"), AnHeart Therapeutics Ltd. ("AnHeart"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer ("Merger Sub I"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer ("Merger Sub II"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the "First Merger"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer (the "Second Merger" and, collectively with the First Merger, as appropriate, the "Merger").

F4 · price: Received in exchange for 2,388,578 Series B Preferred shares of AnHeart in connection with the Merger (as described in footnote 1) on April 9, 2024.

F5 · ownership.nature: These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-010738 · form4-04122024_010452.xml · nonDerivative · entry 1

Cui Xiangmin · CIK 0001487815 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P.

Disclosed balance after: 314,106

F1 · shares: Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among Nuvation Bio Inc. (the "Issuer"), AnHeart Therapeutics Ltd. ("AnHeart"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer ("Merger Sub I"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer ("Merger Sub II"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the "First Merger"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer (the "Second Merger" and, collectively with the First Merger, as appropriate, the "Merger").

F2 · price: Received in exchange for 447,858 Series B Preferred shares of AnHeart in connection with the Merger (as described in footnote 1) on April 9, 2024.

F3 · ownership.nature: These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). The Reporting Person is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-006308 · form4-03042024_100351.xml · derivative · entry 1

Makunje Moses · CIK 0002001938 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Class A Common Stock · 250,000 shares

Expires 2034-02-27

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0001415889-24-006299 · form4-03042024_090300.xml · derivative · entry 2

Hanley David C. · CIK 0001865826 · CHIEF TECHNICAL OPERATIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 500,000 shares

Expires 2034-02-27

F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0001415889-24-006313 · form4-03042024_100333.xml · derivative · entry 1

Wentworth Kerry · CIK 0001369453 · CHIEF REGULATORY OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 500,000 shares

Expires 2034-02-27

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0001415889-24-006310 · form4-03042024_100304.xml · derivative · entry 2

Markel Stacy · CIK 0001734780 · CHIEF PEOPLE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 500,000 shares

Expires 2034-02-27

F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0001415889-24-006294 · form4-03042024_090331.xml · derivative · entry 1

Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 500,000 shares

Expires 2034-02-27

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0001415889-24-006286 · form4-03042024_090323.xml · derivative · entry 2

Liu Dongfang · CIK 0001937915 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 500,000 shares

Expires 2034-02-27

F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0001415889-24-006276 · form4-03042024_090313.xml · derivative · entry 1

Hung David · CIK 0001310880 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Class A Common Stock · 2,000,000 shares

Expires 2034-02-27

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0001415889-24-000935 · form4-01102024_090139.xml · derivative · entry 1

Mashal Robert · CIK 0002007102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 741,179

Underlying: Class A Common Stock · 741,179 shares

Expires 2034-01-07

F1 · derivative.exercise_date: 1/36th of the total number of shares shall vest and become exercisable on each monthly anniversary of January 8, 2024, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0000935836-23-000621 · ownership.xml · nonDerivative · entry 3

NODELMAN OLEG · CIK 0001454385 · Director

EcoR1 Capital, LLC · CIK 0001587114 · Director

EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director

EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director

EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director

Biotech Opportunity GP, LLC · CIK 0001816370 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Notes

Disclosed balance after: 12,674,775

F5 · date: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023.

F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F2 · ownership.nature: Qualified Fund is the record holder of these securities.

SEC source: 0000935836-23-000621 · ownership.xml · nonDerivative · entry 2

NODELMAN OLEG · CIK 0001454385 · Director

EcoR1 Capital, LLC · CIK 0001587114 · Director

EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director

EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director

EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director

Biotech Opportunity GP, LLC · CIK 0001816370 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Notes

Disclosed balance after: 12,621,775

F4 · date: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023.

F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F2 · ownership.nature: Qualified Fund is the record holder of these securities.

SEC source: 0000935836-23-000621 · ownership.xml · nonDerivative · entry 1

NODELMAN OLEG · CIK 0001454385 · Director

EcoR1 Capital, LLC · CIK 0001587114 · Director

EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director

EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director

EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director

Biotech Opportunity GP, LLC · CIK 0001816370 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Notes

Disclosed balance after: 12,504,675

F3 · date: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023.

F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F2 · ownership.nature: Qualified Fund is the record holder of these securities.

SEC source: 0001209191-23-030284 · doc4.xml · derivative · entry 1

WELCH DANIEL G · CIK 0001206199 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 366,744

Underlying: Class A Common Stock · 366,744 shares

Expires 2033-05-14

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 15, 2024); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

SEC source: 0001209191-23-030283 · doc4.xml · derivative · entry 1

VERNON W ANTHONY · CIK 0001369091 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 366,744

Underlying: Class A Common Stock · 366,744 shares

Expires 2033-05-14

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 15, 2024); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

SEC source: 0001209191-23-030282 · doc4.xml · derivative · entry 1

FALBERG KATHRYN E · CIK 0001206977 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 366,744

Underlying: Class A Common Stock · 366,744 shares

Expires 2033-05-14

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 15, 2024); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

SEC source: 0001209191-23-030281 · doc4.xml · derivative · entry 1

BLICKENSTAFF KIM D · CIK 0001238913 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 366,744

Underlying: Class A Common Stock · 366,744 shares

Expires 2033-05-14

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 15, 2024); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

SEC source: 0001209191-23-030259 · doc4.xml · derivative · entry 1

Bazemore Robert B · CIK 0001620152 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 366,744

Underlying: Class A Common Stock · 366,744 shares

Expires 2033-05-14

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 15, 2024); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

SEC source: 0001209191-23-014887 · doc4.xml · derivative · entry 2

Hanley David C. · CIK 0001865826 · Chief Technical Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 500,000 shares

Expires 2033-02-27

F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0001209191-23-014892 · doc4.xml · derivative · entry 2

Markel Stacy · CIK 0001734780 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 500,000 shares

Expires 2033-02-27

F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date

SEC source: 0001209191-23-014890 · doc4.xml · derivative · entry 2

Hung David · CIK 0001310880 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500,000

Underlying: Class A Common Stock · 2,500,000 shares

Expires 2033-02-27

F3 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0001209191-23-014885 · doc4.xml · derivative · entry 2

Fox Jennifer A. · CIK 0001841557 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Class A Common Stock · 600,000 shares

Expires 2033-02-27

F2 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0001209191-23-014884 · doc4.xml · derivative · entry 1

Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Class A Common Stock · 400,000 shares

Expires 2033-02-27

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date

SEC source: 0001209191-23-014883 · doc4.xml · derivative · entry 1

Liu Dongfang · CIK 0001937915 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 500,000 shares

Expires 2033-02-27

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date

SEC source: 0001209191-23-014882 · doc4.xml · derivative · entry 1

Hattersley Gary · CIK 0001521111 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 500,000 shares

Expires 2033-02-27

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0000935836-23-000619 · ownership.xml · nonDerivative · entry 3

NODELMAN OLEG · CIK 0001454385 · Director

EcoR1 Capital, LLC · CIK 0001587114 · Director

EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director

EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director

EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director

Biotech Opportunity GP, LLC · CIK 0001816370 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Notes

Disclosed balance after: 12,674,775

F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F2 · ownership.nature: Qualified Fund is the record holder of these securities.

SEC source: 0000935836-23-000619 · ownership.xml · nonDerivative · entry 2

NODELMAN OLEG · CIK 0001454385 · Director

EcoR1 Capital, LLC · CIK 0001587114 · Director

EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director

EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director

EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director

Biotech Opportunity GP, LLC · CIK 0001816370 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Notes

Disclosed balance after: 12,621,775

F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F2 · ownership.nature: Qualified Fund is the record holder of these securities.

SEC source: 0000935836-23-000619 · ownership.xml · nonDerivative · entry 1

NODELMAN OLEG · CIK 0001454385 · Director

EcoR1 Capital, LLC · CIK 0001587114 · Director

EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director

EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director

EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director

Biotech Opportunity GP, LLC · CIK 0001816370 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Notes

Disclosed balance after: 12,504,675

F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F2 · ownership.nature: Qualified Fund is the record holder of these securities.

SEC source: 0001209191-22-059756 · doc4.xml · nonDerivative · entry 4

FALBERG KATHRYN E · CIK 0001206977 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 250,000

F4 · price: Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $1.925 to $2.00. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: Shares are held directly by The Falberg-Predovich Family Trust, of which the Reporting Person is Co-Trustee.

SEC source: 0001209191-22-059756 · doc4.xml · nonDerivative · entry 3

FALBERG KATHRYN E · CIK 0001206977 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 207,000

F4 · price: Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $1.925 to $2.00. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: Shares are held directly by The Falberg-Predovich Family Trust, of which the Reporting Person is Co-Trustee.

SEC source: 0001209191-22-059756 · doc4.xml · nonDerivative · entry 2

FALBERG KATHRYN E · CIK 0001206977 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 160,000

F3 · price: Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $1.92 to $1.99. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: Shares are held directly by The Falberg-Predovich Family Trust, of which the Reporting Person is Co-Trustee.

SEC source: 0001209191-22-059756 · doc4.xml · nonDerivative · entry 1

FALBERG KATHRYN E · CIK 0001206977 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 75,041

F1 · price: Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $1.805 to $1.90. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: Shares are held directly by The Falberg-Predovich Family Trust, of which the Reporting Person is Co-Trustee.

SEC source: 0001209191-22-048150 · doc4.xml · derivative · entry 1

Hanley David C. · CIK 0001865826 · Chief Technical Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 450,000

Underlying: Class A Common Stock · 450,000 shares

Expires 2032-08-28

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date

SEC source: 0001209191-22-048156 · doc4.xml · derivative · entry 1

Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,000

Underlying: Class A Common Stock · 252,000 shares

Expires 2032-08-28

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date

SEC source: 0001209191-22-048154 · doc4.xml · derivative · entry 1

Markel Stacy · CIK 0001734780 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 450,000

Underlying: Class A Common Stock · 450,000 shares

Expires 2032-08-28

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date

SEC source: 0001209191-22-048153 · doc4.xml · derivative · entry 1

Liu Dongfang · CIK 0001937915 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 315,000

Underlying: Class A Common Stock · 315,000 shares

Expires 2032-08-28

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date

SEC source: 0001209191-22-048151 · doc4.xml · derivative · entry 1

Hattersley Gary · CIK 0001521111 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Class A Common Stock · 400,000 shares

Expires 2032-08-28

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date

SEC source: 0001209191-22-048148 · doc4.xml · derivative · entry 1

Fox Jennifer A. · CIK 0001841557 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 480,000

Underlying: Class A Common Stock · 480,000 shares

Expires 2032-08-28

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date

SEC source: 0001209191-22-042609 · doc4.xml · derivative · entry 2

Liu Dongfang · CIK 0001937915 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 292,500

Underlying: Common Stock · 292,500 shares

Expires 2032-07-14

F2 · derivative.exercise_date: The shares subject to the Options will vest based on the satisfaction of both time-based and performance-based vesting criteria.

SEC source: 0001209191-22-042609 · doc4.xml · derivative · entry 1

Liu Dongfang · CIK 0001937915 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 490,000

Underlying: Common Stock · 490,000 shares

Expires 2032-07-14

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 7/15/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0001209191-22-031879 · doc4.xml · derivative · entry 2

Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,500

Underlying: Common Stock · 247,500 shares

Expires 2032-05-22

F2 · derivative.exercise_date: The shares subject to the Options will vest based on the satisfaction of both time-based and performance-based vesting criteria.

SEC source: 0001209191-22-031879 · doc4.xml · derivative · entry 1

Wentworth Kerry · CIK 0001369453 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 330,000

Underlying: Common Stock · 330,000 shares

Expires 2032-05-22

F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 5/23/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

SEC source: 0001209191-22-030091 · doc4.xml · derivative · entry 1

Bazemore Robert B · CIK 0001620152 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,784

Underlying: Class A Common Stock · 118,784 shares

Expires 2032-05-15

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

SEC source: 0001209191-22-030089 · doc4.xml · derivative · entry 1

BLICKENSTAFF KIM D · CIK 0001238913 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,784

Underlying: Class A Common Stock · 118,784 shares

Expires 2032-05-15

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

SEC source: 0001209191-22-030086 · doc4.xml · derivative · entry 1

VERNON W ANTHONY · CIK 0001369091 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,784

Underlying: Class A Common Stock · 118,784 shares

Expires 2032-05-15

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

SEC source: 0001209191-22-030088 · doc4.xml · derivative · entry 1

FALBERG KATHRYN E · CIK 0001206977 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,784

Underlying: Class A Common Stock · 118,784 shares

Expires 2032-05-15

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

SEC source: 0001209191-22-030085 · doc4.xml · derivative · entry 1

WELCH DANIEL G · CIK 0001206199 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,784

Underlying: Class A Common Stock · 118,784 shares

Expires 2032-05-15

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

SEC source: 0001209191-22-039680 · doc4a.xml · derivative · entry 1

WELCH DANIEL G · CIK 0001206199 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,713

Underlying: Class A Common Stock · 140,713 shares

Expires 2032-05-15

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.